



**FOR IMMEDIATE RELEASE**

**Nurix Strengthens Executive Leadership Team**

*Pierre Beurang, Ph.D., Promoted to Chief Business Officer  
Hans van Houte Joins Company as Vice President of Finance*

**SAN FRANCISCO, CA. – May 3, 2016** – Nurix, Inc., a private drug discovery company, today announced the promotion of Pierre Beurang, Ph.D., to chief business officer. In addition, the company has appointed former interim chief financial officer Hans van Houte to the position of vice president of finance.

“The promotion of Pierre and addition of Hans as a full-time member of our executive team expands and greatly strengthens our leadership team,” said Arthur T. Sands, M.D., Ph.D., CEO of Nurix. “We have made rapid progress building Nurix’s drug discovery platform guided by the collective efforts of our excellent management team.”

Dr. Beurang joined Nurix as vice president of business and corporate development in August 2014 and is responsible for developing Nurix’s partnering strategy. Dr. Beurang led the successful completion of the strategic collaboration with Celgene in September 2015 for the discovery, development and commercialization of novel small molecule therapeutics in oncology, inflammation and immunology that included an upfront payment of \$150 million and significant milestones, royalties and options for commercialization of drugs discovered under the alliance. Prior to joining Nurix, Dr. Beurang was part of the founding team of Five Prime Therapeutics, where he held roles of increasing responsibility and negotiated a number of major collaborations with global pharmaceutical firms. Dr. Beurang holds a Ph.D. in molecular and cell biology from the University of California, Berkeley and conducted postdoctoral research at the University of California, San Francisco. He holds a B.A. and a M.A. in biology and biotechnology, respectively, from Boston University.

Mr. van Houte has served as Nurix’s interim CFO since April 2014 and has served in a similar capacity for multiple new biotechnology companies formed with investments totaling over \$100 million from Third Rock Ventures and The Column Group. Prior to Nurix, he held senior financial roles including vice president, finance and administration at Trubion Pharmaceuticals and controller, treasurer and principal accounting officer at Vertex Pharmaceuticals, where he helped build the organization post-IPO to support growth from a \$100 million company to one with a

multibillion market capitalization and commercial operations. Mr. van Houte received a B.S. in business management from Babson College.

**About Nurix**

Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit [www.nurix-inc.com](http://www.nurix-inc.com).

###

**Media Contact for Nurix:**

Katie Engleman  
Pure Communications, Inc.  
(910) 509-3977  
[katie@purecommunicationsinc.com](mailto:katie@purecommunicationsinc.com).